Immunomodulators Market to Reach $285.01 Billion in 2027; Novartis Receives FDA Approval for Mayzent to Treat Adults with MS

The global immunomodulators market size is projected to grow from USD 186.12 billion in 2020 to USD 285.01 billion in 2027. Several pharmaceutical companies are striving persistently to improve their supply chain management and refine their research capabilities amid the COVID-19 pandemic. As per a report published by Himalaya Drug Company in December 2020, herbal immunomodulators are gaining traction because of their effectiveness in treating COVID-19 patients by operating as an adjuvant agent. Fortune Business Insights™ presented this information in a new report, titled, “Immunomodulators Market Size, Share & COVID-19 Impact Analysis, By Product Type (Immunosuppressant, Immunostimulants), By Application (Oncology, Respiratory, HIV, and Others), and Regional Forecast, 2020-2027.” The report further states that the market stood at USD 161.57 billion in 2019. It is set to exhibit a CAGR of 6.3% between 2020-2027.

Bristol-Myers Squibb Buys Celgene to Create an Innovative Biopharma Leader

In January 2019, Bristol-Myers Squibb purchased Celgene, a reputed cancer drugmaker, worth USD 74 billion. The company is set to develop a state-of-the-art biopharma leader, with a broad pipeline and leading franchises that will further provide new options to patients across a wide range of chronic diseases and boost sustainable growth.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/immunomodulators-market-104692

Increasing Development of Combination Therapy to Augment Growth

Nowadays, several pharmaceutical companies are conducting extensive research and development activities to offer enhanced patient care. It is further giving rise to combination therapies with existing or new drug molecules. This, in turn, is expected to surge the number of pipeline candidates for the treatment of a wide range of chronic diseases, such as Crohn's disease, MS, and rheumatoid arthritis. Some of the drugs, namely, Receptors' RPC-1063 & Nerventra by Teva Pharmaceuticals, Ocrelizumab by Roche, and Plegridy & Daclizumab by Biogen, will be soon made commercially available in the upcoming years. These factors are set to drive the demand for immunomodulators.

However, autoimmune diseases, if treated with high doses of immunomodulators, can result in the occurrences of multiple side-effects, such as fatigue, hair loss, skin disorders, and gastrointestinal disorders. It may obstruct the immunomodulators market growth.

Key Companies Focus on Gaining Approvals from Regulatory Bodies to Market Their Products

The market houses several renowned companies. Out of them, Novartis AG, Amgen Inc., Bristol-Myers Squibb Company, Abbott Laboratories, and F. Hoffmann-La Roche Ltd. were in the dominant positions in 2019. They were leading the immunomodulators industry because of their high geographical presence and extensive research & development activities. Some of the others are trying to gain fast track approval from regulatory bodies to market their products.

Fortune Business Insights™ lists out the names of every manufacturer operating in the global market. They are as follows:

• F. Hoffmann-La Roche Ltd (Basel, Switzerland)


• Novartis AG (Basel, Switzerland)


• Biogen (Massachusetts, U.S.)


• Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel)


• Amgen, Inc (California, U.S.)


• Bristol-Myers & Squibb Company (New York, U.S)


• Merck Sharp & Dohme Corp. (New jersey, U.S)


• Eli Lilly and Company (Indiana, U.S)


• Other Players

A Notable Industry Development-

• March 2019: Novartis, a multinational pharmaceutical company, based in Switzerland, announced the U.S. FDA approval of Mayzent® (siponimod). It will be used to treat adults suffering from relapsing forms of multiple sclerosis, such as clinically isolated syndrome (CIS), relapsing-remitting multiple sclerosis (RRMS), and secondary progressive multiple sclerosis (SPMS). This approval is anticipated to bolster a conversation between healthcare professionals and patients about disability progression.

Further Report Findings-

• North America generated USD 61.91 billion in 2019 in terms of revenue. The region is likely to remain at the forefront because of the presence of numerous prominent providers in the region. At the same time, the increasing prevalence of chronic diseases in the U.S. would aid regional growth.


• In Europe, surging investments in research and development activities to introduce highly effective drugs would propel growth. The region is set to remain in the second position.


• Based on the product type, the immunosuppressants segment held the highest market share in 2019. The increasing usage of these drugs for the treatment of lupus, multiple sclerosis (MS), rheumatoid arthritis, and alopecia areata would accelerate this segment's growth. Additionally, these drugs are capable of suppressing the strength of the immune system.

The global market can be segmented in the following way: